Eli Lilly's most recent trend suggests a bullish bias. One trading opportunity on Eli Lilly is a Bull Put Spread using a strike $107.00 short put and a strike $102.00 long put offers a potential 46.63% return on risk over the next 22 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $107.00 by expiration. The full premium credit of $1.59 would be kept by the premium seller. The risk of $3.41 would be incurred if the stock dropped below the $102.00 long put strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Eli Lilly is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Eli Lilly is bearish.
The RSI indicator is at 34.06 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Eli Lilly
Earnings Preview: Eli Lilly (LLY) Q2 Earnings Expected to Decline
Tue, 23 Jul 2019 14:32:02 +0000
Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Eli Lilly (LLY) is a Top Dividend Stock Right Now: Should You Buy?
Fri, 19 Jul 2019 13:15:01 +0000
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.
NuCana Initiates Dosing in Phase I Study for Solid Tumors
Thu, 18 Jul 2019 15:18:03 +0000
NuCana (NCNA) doses the first patient in a phase I study on NUC-7738, which is being evaluated for the treatment of advanced solid tumors.
AC Immune Initiates Phase I Study for Alzheimer's Disease
Thu, 18 Jul 2019 14:26:02 +0000
AC Immune (ACIU) initiates phase I study of ACI-3024, a Tau Morphomer inhibitor, for the treatment of neurodegenerative diseases like Alzheimer's disease.
AC Immune Initiates Phase 1 Study of ACI-3024 Small Molecule Tau Morphomer™, an Investigational Treatment for Alzheimer’s Disease
Wed, 17 Jul 2019 11:00:00 +0000
LAUSANNE, Switzerland, July 17, 2019 — AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company, today announced dosing of the first subject in a.
Also on Market Tamer…
Follow Us on Facebook